The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
 
Jia Fan
No Relationships to Disclose
 
Jian Zhou
No Relationships to Disclose
 
Guoming Shi
No Relationships to Disclose
 
Xiaoyong Huang
No Relationships to Disclose
 
Liang Ma
No Relationships to Disclose
 
Jun-Ye Wang
No Relationships to Disclose
 
Qiang Gao
No Relationships to Disclose
 
Shuangjian Qiu
No Relationships to Disclose
 
Huichuan Sun
No Relationships to Disclose
 
Yinghong Shi
No Relationships to Disclose
 
Xiao-Wu Huang
No Relationships to Disclose
 
Xiaoying Wang
No Relationships to Disclose
 
Yong Yi
No Relationships to Disclose
 
Xiaodong Zhu
No Relationships to Disclose
 
Cheng Huang
No Relationships to Disclose
 
Zhenbin Ding
No Relationships to Disclose
 
Yi Chen
No Relationships to Disclose
 
Yi-Feng He
No Relationships to Disclose
 
Yinghao Shen
No Relationships to Disclose
 
Qiman Sun
No Relationships to Disclose